Amezalpat has been granted FDA fast track designation as treatment for patients with hepatocellular carcinoma.

The firm will study its autologous cell therapy alone and in combination with Eisai's Lenvima in patients with hepatitis B-driven hepatocellular carcinoma.

The FDA has granted Fast Track designation to amezalpat (TPST-1120) for the treatment of patients with hepatocellular carcinoma.

U.S. Food and Drug Administration (FDA) recently accepted the Biologics License Application (BLA) for RP1 plus nivolumab in advanced melanoma for ...

Lion TCR announced that its mRNA-encoded T-cell receptor (TCR)-T cell therapy product Liocyx-M004 has received clearance from the U.S. Food and Drug Administration (FDA) to initiate an international ...